We recently showed that, in IGF-based GH therapy, the IGF-I target chosen affects GH dose requirements, and higher IGF-I targets are associated with more robust growth parameters.
T he dosage of GH for treatment of children with GH deficiency (GHD) has been historically based on the body weight of patients, and in the United States, GH has been traditionally dosed in the range of 25-100 g/kg ⅐ d, depending on age and pubertal status (1) (2) (3) (4) . However, not all children show a uniform response to a given dose of GH, which probably reflects differences in the severity of the deficiency and the sensitivity of individual patients to treatment (5) . IGF-I has been identified as the major mediator of GH-induced somatic growth (6 -9) . A GH dosing algorithm based on IGF-I response should therefore more accurately reflect the true GH requirement of a patient and allow optimization of GH treatment.
Idiopathic short stature (ISS) is a term used to describe children with non-GHD short stature, in which the etiology of the growth abnormality cannot be identified (10) . With the advance of molecular genetics, more and more patients diagnosed with ISS have distinctive etiologies for their short stature, including abnormalities of the GH receptor and in postreceptor GH signaling (11) . Testing of serum GH and IGF-I levels has been widely used in clinical practice to understand the underlying molecular basis of short stature. A peak GH concentration less than 10 ng/ml after any one or more of series of secretagogues and assayed by RIA has traditionally been used to support the diagnosis of GHD (12); however, the equivalent level in monoclonal-based assays is considered to be 7 ng/ml (13) . Subjects, with no clear etiology of short stature, who have stimulated GH levels above these cutoff values are classified as ISS. Serum IGF-I levels have been used as an additional tool in screening and classifying short patients (14) .
We recently published the results of a multicenter study showing that in IGF-deficient patients treated with GH, targeting IGF-I SD score (SDS) to the upper range of normal resulted in a significantly greater increase in height SD scores (HTSDS) than targeting the IGF-I levels to the population mean or using a conventional body weight based GH dose of 40 g/kg ⅐ d (15) . Because failing a GH-stimulation test was not a required inclusion criterion in this study, the study population was heterogeneous in terms of serum GH levels in response to provocative stimuli. In this report, we used the arbitrary cutoff of 7 ng/ml for peak stimulated GH concentration to separate this subject population into GHD and ISS subgroups to analyze the differential growth response to GH therapy in relation to their endogenous GH secretion status.
Patients and Methods
This clinical trial (37 sites in the United States) was approved by the institutional review board in all centers and was conducted in accordance with the Declaration of Helsinki (16) . Written informed consent was provided by a parent/legal guardian before any study-related activities, and assent was obtained from children older than 8 yr.
Study design
The study was described in detail in a previous publication (15) . It was a 2-yr, open-label, randomized IGF-I concentrationcontrolled trial. The null hypothesis was that, during GH therapy in short, IGF-I-deficient children, titrating GH dose to achieve different levels of IGF-I SDS would result in no difference in height increase over 2 yr. Subjects were randomized 2:2:1 to one of the three treatment arms: 1) the IGF0T group (n ϭ 70) had an IGF-I SDS target of 0 SDS; 2) the IGF2T group (n ϭ 68) had an IGF-I SDS target of ϩ2 SDS; 3) the conventional (Conv) treatment group (n ϭ 34) received a weight-based GH dose of 40 g/kg ⅐ d.
Therapy with GH (Norditropin delivered by NordiPen using NordiPenMate; Novo Nordisk A/S, Bagsvaerd, Denmark) was initiated at 40 g/kg ⅐ d in all treatment groups. For the IGF-I target groups, dose changes were calculated based on the difference between measured and target IGF-I SDS. A 20% dose change was used for each SD unit difference between actual and target IGF-I. GH doses were adjusted beginning at the month 1 visit and at each subsequent 3-month visit until the end of study. In the Conv group, doses were maintained at 40 g/kg ⅐ d and adjusted only for body weight.
Subject population
Enrolled subjects had a HTSDS less than Ϫ2, serum IGF-I SDS Ϫ1.0 or less, a bone age 9 yr or less for boys or 7 yr or less for girls, and had not entered puberty (using criteria of Tanner stage I for breasts in girls and testicular volume 3 ml or less for boys by Prader orchidometer) within 3 months of screening (17, 18) . Pubic hair development in both girls and boys, up to and including Tanner stage 2, was permitted at study entry, Exclusion criteria included prior use of GH, previous GH stimulation testing, or growth retardation attributable to other causes, e.g. diabetes, metabolic or bone disease, chromosomal disorder or syndrome, intrauterine growth retardation, etc.
An arginine/L-dopa GH stimulation test was performed at baseline to determine pretreatment GH status and allow a subgroup analysis of the potential effect of GH status on treatment outcomes. Arginine (0.5 mg/kg iv over 30 min) and L-dopa (100 mg, oral, if body weight Ͻ30 lb or 250 mg if body weight Ն30 lb) were administered in the morning after overnight fasting. Blood samples were drawn at 15, 30, 45, 60, 75, 90, 105 , and 120 min for serum GH concentration measurements.
Based on the peak GH value during the stimulation test, the study population was divided into two subgroups: 1) GHD subgroup: peak GH stimulation test value less than 7 ng/ml (n ϭ 63, 37%); and 2) ISS subgroup: peak GH stimulation test value 7 ng/ml or greater (n ϭ 102, 59%). Seven patients were excluded from subgroup analysis due to missing GH stimulation test results at baseline.
Clinical and laboratory assessment
Standing height was measured in quadruplicate using a wallmounted stadiometer. Bone age was determined centrally by a single blinded observer using a left hand-wrist radiograph according to methods of Greulich and Pyle (19) . All safety labo-ratory tests were performed centrally (MRLI, Highland Heights, KY) (see data included in Table 2 ).
Serum IGF-I (DSL-5600), IGF binding protein (IGFBP)-3 (DSL-6600), and GH (DSL-1900 double monoclonal immunoradiometric assay) assays were performed at Diagnostic Systems Laboratories (Webster, TX). The normative data set used to calculate the Diagnostic Systems Laboratories IGF-I SDS in children for this study has been assembled with samples from 1875 (1045 male and 830 female) healthy subjects aged 0 -20 yr. The samples were primarily collected in the United States and Europe. The IGF-I SDS calculation and the assay characteristics and performance were provided by Diagnostic Systems Laboratories and conformed to industry standards (14) .
Study visits occurred at months 0 (randomization), 1, 3, 6, 9, 12, 15, 18, 21, and 24 (end of study) . Assessments for adverse events, height, weight, funduscopy, vital signs, and IGF-I levels were conducted at all visits, as was physical examination for scoliosis and slipped capital femoral epiphysis. A complete physical examination was conducted every 6 months, with brief examinations at other visits. X-ray assessment of bone age was obtained at baseline and repeated at the final visit.
Statistical analysis
The primary analysis of the prespecified null hypothesis was conducted on the intent-to-treat population, which included all randomized subjects who received study medication and who had at least one postbaseline height and IGF-I assessment. The primary end point for the study was the change in HTSDS. Analysis of covariance was used to test for treatment effect with baseline HTSDS as a covariate in assessing the change from baseline in HTSDS (⌬HTSDS) at each visit. Last observation carried forward (LOCF) was used to impute missing values for the intentto-treat population. Allowing for a 10% noncompleter rate, the sample size was selected to allow for 80% power to detect a 0.4 U difference in HTSDS between the two IGF-targeted groups with a combined SD of 0.6 at an alpha level of 0.05. All reported P values are two sided and not adjusted for multiple testing.
A subgroup analysis was performed to compare the effect of GH therapy on HTSDS, IGF-I SDS change from baseline, and GH dose requirements in GHD and ISS patients. To reveal the relationship between ⌬HTSDS at end of study and baseline IGF-I or peak GH levels, the subject populations were divided into baseline IGF-I SDS tertiles, and baseline GH tertiles based on their IGF-I SDS values and their peak GH levels during the GH stimulation test. The cutoff values of IGF-I SDS used to divide the total population into three equal groups were Ϫ3.9 and Ϫ2.7 [patients with baseline IGF-I ϽϪ3.9 were assigned to the lower tertile, patients with IGF-I SDS ՆϪ2.7 were assigned to the upper tertile, and those in between (Ϫ3.9 Ն IGF-I SDS Ͻ Ϫ 2.7) belonged to the middle tertile]. Similarly, subjects were categorized into three tertiles according to their peak stimulated GH values, and the cutoff values for the three GH tertiles were 6.3 and 11.1 ng/ml.
Results

Demographics and baseline information
A total of 172 subjects were randomized; 171 were exposed to the study drug, and 147 patients completed the 2-yr study. Based on the results of the GH stimulation test performed at baseline, the study population consisted of two subgroups: 63 (37%) patients with GHD and 102 (59%) with ISS. Seven (4%) had missing GH stimulation test results at baseline. The demographics and baseline information are summarized in Table 1 by treatment group and subdivided into GHD and ISS. All subjects were prepubertal at baseline. The GHD and ISS subgroups were IGF-I SDS levels achieved during the study IGF-I SDS values over time for the two IGF-targeted groups are shown in Fig. 1A . Mean IGF-I SDS showed a rapid increase in all groups during the first month after initiation of GH treatment. Using the prespecified dosing algorithm, target IGF-I values were generally reached within 6 -9 months. In the IGF2T treatment group at 24 months, GHD patients reached a mean (SE) IGF-I value of 2.83 (0.39) SDS, whereas ISS subjects reached a mean (SE) IGF-I value of 1.93 (0.38) SDS (P ϭNS between GHD and ISS). In the IGF0T treatment group at 24 months, GHD patients reached a mean IGF-I value of 0.46 (0.24) SDS, whereas ISS patients reached an IGF-I value of 0.05 (0.24) SDS (P ϭNS between GHD and ISS). The mean IGF-I in the IGF2T treatment group at 24 months was significantly different from the IGF0T treatment group (P Ͻ 0.001).
HTSDS change from baseline
HTSDS changes from baseline at end of study (using the LOCF approach) are presented in Fig. 1B . The mean (SE) ⌬HTSDS for GHD patients in IGF0T, IGF2T, and Conv groups were 1.41 (0.13), 2.04 (0.17), and 1.23 (0.12), respectively. The mean (SE) ⌬HTSDS for ISS patients in IGF0T, IGF2T, and Conv groups were 0.84 (0.07), 1.33 (0.09), and 0.87 (0.09), respectively. The GHD population had significantly (P Ͻ 0.05) greater ⌬HTSDS than the ISS population in all three treatment groups. Significant differences were also observed between IGF2T and IGF0T and between IGF2T and Conv in both the ISS and GHD populations. No significant differences were observed between IGF0T and Conv in either population.
GH dose requirement
GH doses required to maintain the target IGF-I SDS at the end of the study are presented using a histogram in Fig.  2 . In general, subjects in the IGF2T group required higher GH does to maintain the target IGF-I SDS level than subjects in the IGF0T group (P Ͻ 0.001). In GHD patients, the mean (SE) GH dose at the end of study was 37 (4) g/kg ⅐ d (median 33) for the IGF0T group and 91 (17) g/kg ⅐ d (median 65) for the IGF2T group (P Ͻ 0.001). In ISS patients, the mean (SE) GH dose was 32 (3) g/kg ⅐ d ( median   FIG. 1 . IGF-I SDS and ⌬HTSDS by treatment groups and GHD and ISS subgroups. A, IGF-I assays were performed at 0, 1, 3, 6, 9, 12, 15, 18, 21 , and 24 months. IGF-I SDS values were calculated based on the standard provided by Diagnostic Systems Laboratories. The legends for IGF0T and IGF2T treatment groups are square and triangle, respectively. GHD subgroups are in solid lines, and ISS subgroups are in dashed lines. B, Mean (SE) values of height SDS changes from baseline at the end of study using last observation carried forward method are presented. *, P Ͻ 0.05.
FIG. 2.
Histogram of GH dose by treatment groups and GHD and ISS at the end of the study. Dose distribution in IGF0T-GHD group (n ϭ 29), IGF0T-ISS group (n ϭ 39), IGF2T-GHD group (n ϭ 22), and IGF2T-ISS group (n ϭ 41). Vertical bars represent the percentage of patients in each GH dose range at the end of the study (LOCF). A, IGF0T treatment group. B, IGF2T treatment group. 26) for the IGF0T group and 114 (8) g/kg ⅐ d y (median 119) for the IGF2T group (P Ͻ 0.001). As seen in Fig. 2B , there was a clear rightward shift of GH doses in ISS subjects when compared with those with GHD within the IGF2T group, indicating that the ISS subject required a higher GH dose than those with GHD.
Effect of targeting IGF-I during GH treatment on height gain distribution
The effect of targeting IGF-I SDS at two different levels on ⌬HTSDS after 1 yr of GH treatment is shown in Fig. 3 . The mean (SE) and median ⌬HTSDS at yr 1 for GHD subjects in IGF0T and IGF2T treatment groups were 1.04 (0.10) (median 0.97), and 1.47 (0.11) (median 1.35), respectively (P Ͻ 0.001). In GHD subjects, a high percentage (65.0%) achieved a ⌬HTSDS 1.2 or greater in the IGF2T group, whereas the percentage was lower in the IGF0T group (21.4%). Subjects with ISS achieved lower ⌬HTSDS at 1 yr than GHD subjects (P Ͻ 0.001). For ISS subjects, the mean (SE) and median ⌬HTSDS in IGF0T and IGF2T treatment groups were 0.69 (0.05) (median 0.60) and 0.94 (0.05) (median 0.96), respectively (P Ͻ 0.001). In ISS subjects, targeting IGF-I SDS at a higher level (ϩ2 SDS, IGF2T group) yielded a similar pattern of growth response when compared with GHD subjects with a lower IGF-I SDS target (0 SDS, IGF0T group). The height velocities of these patients followed a similar pattern: first year height velocity in GHD IGF0T ϭ 10.73(0.45) cm/yr, GHD IGF2T ϭ 12.89 (0.50) cm/yr, ISS IGF0T ϭ 8.87 (0.28) cm/yr, ISS IGF2T ϭ 10.35 (0.27) cm/yr. These results showed that ISS subjects are generally less sensitive to GH therapy than GHD patients and may benefit from a higher IGF-I SDS target during GH therapy.
Relationship between baseline IGF-I SDS, baseline peak-stimulated GH level, and HTSDS at end of study
The changes in HTSDS from baseline to end of study (LOCF) from all the three treatment groups were pooled and plotted against the baseline IGF-I SDS and peak-stimulated GH levels in Fig. 4A . In this three-dimensional graph, baseline IGF-I SDS and peak stimulated GH values are divided into three tertiles (lower, middle, and upper). The cutoff values for the three IGF-I tertiles are Ϫ3.91 and Ϫ2.76 SDS, and the cutoff values for peak stimulated GH tertiles are 6.3 and 11.1 ng/ml. The greatest ⌬HTSDS values were observed in patients with lower IGF-I/lower GH (⌬HTSDS 1.55), lower IGF-I/middle GH (⌬HTSDS 1.45), and middle IGF-I/lower GH (⌬HTSDS 1.69). It appeared that the higher the baseline IGF-I or GH values the subjects had, the less the ⌬HTSDS they would achieve with GH therapy.
The three subject groups were also compared across four baseline peak GH ranges using the peak stimulated GH cutoff values of the following: GH, less than 5, 5-9, 9 -13, and greater than 13 ng/ml. Mean ⌬HTSDS at 2 yr for these four GH subgroups are presented in Fig. 4B . As the figure shows, patients with lower peak stimulated GH levels showed a greater response to GH as measured by ⌬HTSDS from baseline at 2 yr (P Ͻ 0.01).
These results suggest that ⌬HTSDS is negatively correlated with baseline IGF-I SDS and baseline peak stimulated GH values. The combination of severe GH deficiency and IGF-I deficiency predicted greater growth response during GH therapy. These results are consistent with the multivariate analysis of this study as previously published, in which baseline IGF-I and peak GH were both identified as baseline predictors of GH response (12) .
Safety assessments
General safety aspects of the study have been reported previously. The treatment-emergent adverse event profiles were similar for the three treatment groups and for GHD and ISS subpopulations.
Bone age changes from baseline to 24 months are presented in Table 2 . In general, bone age advanced more than   FIG. 3 . Effect of targeting IGF-I during GH treatment on yr 1 height gain in GHD and ISS populations. The yr 1 ⌬HTSDS are divided into five categories: less than 0.3, 0.3-0.6, 0.6 -0.9, 0.9 -1.2, and 1.2 or greater SDS. The percentages of patients that belonged to these categories are presented by treatment groups (white bars for IGF0T and black bars for IGF2T). A, GHD patients. B, ISS patients. The total number of patients within each treatment group (IGF0T or IGF2T) for that particular patient population (GHD or ISS) is considered 100%. chronological age (mean change in bone age ranged from 2.31 to 2.93 yr over 2 yr). Higher GH doses used in the IGF2T group were not associated with greater bone age change. No significant differences were identified between the treatment groups. Three boys (mean age 13 yr) and four girls (mean age 10.6 yr) were reported to be in puberty at the end of the 2-yr study. Five of theses were noted to have ISS, six were in the low-IGF titration arm, and one was in the conventional arm. None were in the high-IGF titration arm. We concluded that there were no significant interrelationships between puberty and the outcomes of the dose titration study that are detectable in this study due to the very low percentage of children who entered puberty.
Similar to the changes observed in IGF-I, the mean values of IGFBP-3 also increased from baseline (Table 2) . Greater increases in IGFBP-3 levels were observed in the GHD population than in the ISS population. In the GHD population, overall treatment effects on ⌬IGFBP-3 were significant. Pair-wise comparison revealed that the IGF2T treatment group had a significantly greater mean ⌬IGFBP-3 than the IGF0T group. In the ISS population, overall treatment effect was significant for ⌬IGFBP-3 values (P ϭ 0.023), and pair-wise comparison revealed that the IGF2T treatment group had greater mean ⌬IGFBP-3 than the IGF0T group.
Fasting serum glucose levels remained the same or lower during the study and did not differ among the three groups or between GHD and ISS patients ( Table 2 ). Fasting serum insulin levels increased from baseline in all three treatment groups in GHD patients, but the mean serum insulin values remained within the normal range for all groups. No consistent trend was observed for the ISS subjects.
BMI increased by approximately 1 kg/m 2 from baseline to 24 months in the GHD subjects, with no significant differences observed among the three treatment groups. In the ISS population, the IGF2T treatment group had greater BMI increase (1.76 kg/m 2 ) than the IGF0T and Conv groups (0.95 and 0.91 kg/m 2 , respectively), with an overall P value of 0.052. Pairwise P values were significant for comparisons between IGF2T and IGF0T and between IGF2T and Conv (0.047 and 0.033, respectively); however, it is of note that ISS children displayed a trend toward lower BMI levels at the beginning of the study. There was no statistically significant correlation between BMI and delta height SDS in either the GHD or ISS groups.
Discussion
Enrolled children fulfilled the height and IGF-I SDS inclusion criteria, but they were not necessarily GH deficient. Because GH deficiency was not an inclusion criterion, the study population showed a wide range of responses to the GH stimulation test (peak GH 0.1-34 ng/ml), indicating a heterogeneous patient population regarding GH secretory response. The majority of the subject population (59%) had a peak GH concentration above 7 ng/ml, consistent with ISS. A second group (37%) of patients with stimulated GH levels less than 7 ng/ml met the conventional definition of GHD, whereas 4% had a missing GH stimulation test result. The objective of this subgroup analysis was to assess response to GH therapy in GHD and ISS subject populations and to correlate GH response to the treatment regimen and baseline characteristics.
As shown in Fig. 1 , the IGF0T group and IGF2T group reached the respective IGF-I SDS targets within 6 -9 months after GH therapy was initiated. No differences were observed between GHD and ISS subgroups in terms   FIG. 4 . Peak-stimulated GH value predicts GH response. A, The ⌬HTSDS from baseline at end of study is presented according to patient's baseline IGF-I SDS value and peak-stimulated GH value from GH stimulation test. The values of IGF-I SDS to divide the patient population into three equal groups were Ϫ3.91 and Ϫ2.76, and the cutoff values of peak GH to divide patients into three GH tertiles were 6.3 and 11.1 ng/ml. This analysis consisted of all the patients in the study, regardless of their treatment groups and GHD ISS subgroups. B, Patients were categorized into four subgroups according to their peak stimulated GH levels at baseline: GH less than 5, 5-9, 9 -13, and greater than 13 ng/ml. Mean ⌬HTSDS at 2 yr for these four GH subgroups are presented.
of attaining targets in these two groups. Because the GH dose was titrated to target in the two IGF-I targeting groups, differences in IGF-I SDS values between GHD and ISS subgroups were not expected. The conventional group received a fixed body weight-based GH dose of 40 g/ kg ⅐ d. The similar successful achievement of the target IGF levels in a both patient subpopulations indicates that the dose titration algorithm we chose is an effective tool for both GHD and ISS patients.
On the other hand, there were clear differences between GHD and ISS subjects for the GH dose required to maintain IGF-I SDS targets in the IGF0T and IGF2T groups. The IGF2T group required higher GH doses to maintain the target IGF-I SDS than the IGF0T group. In the IGF0T group, the mean GH dose did not differ between GHD and ISS subgroups, which suggests that at low GH dose, GHD patients and ISS patients have a similar ability to generate IGF-I in response to GH therapy. Within the IGF2T group, however, the mean GH dose in the GHD patients was skewed by a few patients who required very high GH doses. In this case, median dose was a better indicator of the average GH requirement in this group of patients. In the IGF2T group, ISS subjects required a much higher median dose (119 g/kg ⅐ d) to maintain an IGF-I SDS at the upper normal range than GHD patients (65 g/kg ⅐ d). It appeared that the difference in GH sensitivity between GHD and ISS subjects is unmasked when a higher IGF-I SDS value is targeted.
When the growth response was compared between GHD and ISS, the greatest height SDS change from base- J Clin Endocrinol Metab, May 2010 , 95(5):2089 -2098 line was demonstrated in GHD subjects in the IGF2T group. Within each treatment group, GHD patients had greater ⌬HTSDS than ISS subjects, indicating that GHD subjects are more responsive to GH therapy. Both GHD and ISS subjects achieved the same designated IGF-I targets. This suggests a degree of IGF insensitivity in ISS subjects. When the three treatment groups were compared, the IGF2T group showed a greater ⌬HTSDS than the IGF0T and the conventional treatment groups in both GHD and ISS populations. These findings suggest that subjects with ISS have a diverse spectrum of etiologies. There are several factors that could be related to this (20) , including common polymorphisms in GH-IGF axis genes such as the delta-exon 3-GH receptor (21, 22) , that have been suggested to affect GH responsiveness in children with ISS or a host of novel genes shown recently to affect height in the general population (23, 24) . Of note is that ISS subjects in the IGF2T group were able to achieve a ⌬HTSDS response comparable with that achieved by GHD patients using conventional treatment or having a low IGF-I target. By assessing the height gain at yr 1, we have provided further evidence that targeting IGF-I SDS to a higher range leads to greater ⌬HTSDS in both GHD and ISS subpopulations, and GHD subjects were more responsive to GH therapy than ISS subjects when the same dosing regimens were used. These results suggest that a more aggressive IGF-I SDS target could be used in treating patients with ISS, whose growth response to conventional body weight-based GH regimen is often suboptimal.
Correlation and multivariate analyses have been performed and presented previously to identify baseline and on-treatment characteristics that are predictive of response to GH therapy. In this study we were able to directly assess the effects of baseline IGF-I SDS and peak GH value on the growth response. The present analysis has included all patients from three treatment groups and was not divided into GHD or ISS subpopulations. Because the cutoff for the lower peak GH tertile was 6.3 ng/ml, most GHD patients would fall into the lower GH tertile. Similarly, patients with IGF-I SDS less than Ϫ3.91 belonged to the lower IGF-I SDS tertile. Patients with severe GHD (lower GH tertile) responded well to GH therapy. Subjects in the lower IGF-I tertile and middle (moderate) GH tertile also responded very well to GH therapy: these subjects were more IGF-I deficient than GH deficient. Therefore, GH therapy is a viable option for the treatment of IGF-I deficiency, although higher than conventional dosages of GH may be required. Subjects in the upper GH tertile had the least change in HTSDS, indicating that they are resistant to GH therapy. The molecular basis for their short stature could possibly be defects of the GH receptor or of the mechanisms that regulate IGF-I production and function. By including a much wider dosing range than attempted previously, our analysis allowed the capture of new determinants of the growth response in children with ISS, which did not appear to be as important in previous analysis of GH registries (25) , such as the GH dose, the prestimulated treatment GH levels, and the rise in IGF-I during treatment (15) . In an analysis of the National Cooperative Growth Study registry, Bright et al. (26) noted that there was little effect of the pretreatment peak-stimulated GH level on the first-year growth velocity, with the exception that children with severe GHD who grew more rapidly. Our data (Fig. 4B) , however, demonstrates that IGF-based dosing strategies accentuates the relationship between the pretreatment peak GH and the 2-yr growth response that is observed across the spectrum of GH ranges from severe GHD (peak Ͻ5 ng/ml) and moderate GHD (peak 5-9 ng/ml) to ISS (peak Ͼ9 ng/ml).
Furthermore, it is interesting to note that whereas IGF-I levels during the course of therapy are clearly useful in the management of children treated with GH, we observed little or no value in the monitoring of IGFBP-3 levels in this scenario.
The concept of individualizing and optimizing GH therapy for children with ISS as well as GHD subjects is gaining credence and several groups are proposing approaches to implement this strategy (27) , including using modeling for determination of the initial starting GH dose (28) . Indeed, a recent consensus statement by the leading international pediatric endocrine societies endorsed the judicious use of IGF-I measurements and GH dose adjustments in children with ISS (29) . The outcome of GH therapy in children with ISS is important both auxologically and psychologically (30) and deserves careful attention.
It is important to note that this study was not designed to convince clinicians to use higher doses of GH than are currently recommended to achieve IGF-I levels at the upper normal range but rather to develop approaches that will give them a safe strategy of enhancing growth in selected patients using the IGF-based GH dose titration technique.
In conclusion, we have shown that IGF-based GH dosing is clinically feasible. Titrating the GH dose to achieve higher IGF-I targets resulted in greater growth responses, generally at higher GH doses. Subjects with GHD were more responsive to GH treatment than those with ISS. GHD subjects required lower GH doses and achieved greater height gain when compared with ISS subjects. IGF-I based GH dosing provides an individualized approach to optimize patient response to GH therapy and minimize the risk of increasing IGF-I levels above the normal range. Further understanding the etiology and mo-lecular basis of short stature will help select the patient population that would have the greatest potential to benefit from GH therapy.
